证券代码：301156 证券简称：美农生物 公告编号：2025-038 上海美农生物科技股份有限公司 2024 年年度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 上海美农生物科技股份有限公司（以下简称"公司"）于 2025 年 5 月 16 日 召开 2024 年年度股东大会审议通过了《关于公司 2024 年度利润分配预案的议 案》，现将权益分派事宜公告如下： 一、股东大会审议通过利润分配预案情况 1、公司 2024 年度利润分配预案：以实施权益分派股权登记日登记的公司总 股本为基数，向全体股东每 10 股派发现金红利 3.2 元（含税），不送红股，不 以资本公积金转增股本。以本公告披露日的公司总股本 140,784,675 股计算，合 计派发现金 45,051,096 元，公司剩余未分配利润结转以后年度分配。如在利润 分配预案公告后至实施前公司总股本发生变化，公司将按照"分配比例不变"的 原则，相应调整分配总额。 2、自公司利润分配预案披露至实施期间公司股本总额未发生变化。 3、本次实施的分配方案与股东大会审议通过的分配预案及其调整原则 ...

Group 1 - The pet economy concept is experiencing significant downturns, with Tianyuan Pet (301335) and Meinong Bio (301156) opening lower and declining nearly 10% [1] - Other companies such as Yuanfei Pet (001222), Daqian Ecology (603955), Huisheng Bio (300871), and Lusi Co. are also seeing notable declines [1] - There is a stealthy inflow of dark pool funds into these stocks, indicating potential interest despite the current market conditions [1]

金十数据5月27日讯，美农生物公告，公司董事、高级管理人员熊英计划自公告披露之日起15个交易日 后的3个月内，以集中竞价、大宗交易方式减持不超过124.53万股，占公司总股本的0.88%。熊英目前持 有公司3.54%股份，减持原因为个人资金需求。减持价格将不低于公司发行价，减持计划实施存在不确 定性。 美农生物：熊英拟减持0.88%公司股份 ...

证券代码：301156 证券简称：美农生物 公告编号：2025-037 上海美农生物科技股份有限公司 关于部分董事、高级管理人员股份减持计划的预披露公告 公司董事、高级管理人员熊英保证向本公司提供的信息内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息 一致。 特别提示： 1、截至本公告披露日，上海美农生物科技股份有限公司（以下简称"公司"） 总股本为 140,784,675 股。 2、持有公司股份 4,981,049 股（占公司总股本比例 3.54%）的董事、高级管 理人员熊英，计划自本公告披露之日起 15 个交易日后的 3 个月内以集中竞价、 大宗交易的方式减持其持有的公司股份不超过 1,245,262 股（占公司总股本比例 0.88%）。 二、本次减持计划的主要内容 1、减持目的：个人资金需求。 2、股份来源：公司首次公开发行前持有及上市后权益分派取得的股份。 近日，公司收到公司董事、高级管理人员熊英出具的《关于减持所持上海美 农生物科技股份有限公司股份的减持计划告知函》，现将具体事项公告如下： 一、股东的基本情况 截至本公告日，拟 ...

Core Insights - The company reported a year-on-year decline in net profit primarily due to intensified domestic market competition, decreased investment income, and reduced subsidy income [1] - Despite the domestic business downturn, the company's international operations showed robust growth, with overseas revenue increasing by 25% year-on-year [1] - The company plans to enhance its investment in international markets in 2025 to maintain its competitive edge and drive continued growth [1] Company Overview - The company, established in 1997, specializes in the research, production, and sales of feed additives, with over 27 years of industry experience [2] - Its products are widely used in various animal sectors, including pigs, ruminants, poultry, and aquaculture, playing a crucial role in improving feed intake, digestion, gut health, growth promotion, milk quality, and feed resource efficiency [2] Future Plans - The company is advancing a corn protein processing project with an annual capacity of 100,000 tons, expected to be completed in 2025, which will optimize product structure and create new revenue growth points [1]

Group 1: Company Strategy and Product Development - The company adopts a "segmented species, comprehensive nutrition" product development strategy, establishing a diverse product system to enhance competitive advantages in a challenging market [2][3] - Various comprehensive solutions are provided to meet different customer needs, such as improving animal feed intake and maintaining gut health [3] - The company focuses on continuous product innovation and development, particularly in the fields of feed additives and enzymatic protein feed materials [4][7] Group 2: Market Position and Growth Opportunities - The company has a global market presence, covering various animal categories including pigs, poultry, ruminants, and aquaculture [4] - International market revenue increased by 25% year-on-year, while domestic market revenue has faced challenges for three consecutive years [6][9] - The company plans to expand its product applications in ruminants and aquaculture to mitigate risks associated with the cyclical nature of the pig farming industry [5][9] Group 3: Financial Performance and Management - In Q1 2025, the company reported revenue of 99.85 million, a year-on-year increase of 1.99%, while net profit decreased by 5.4% [6][9] - The company emphasizes cash flow management through inventory optimization and accounts receivable recovery, aiming to enhance operational cash flow [5][9] - R&D investment decreased by 4.93%, but the number of R&D personnel increased by 7.25%, indicating a focus on maintaining technological advantages [8][10] Group 4: Future Outlook and Risk Management - The company acknowledges uncertainties in the market, such as competition and raw material price fluctuations, but views these as both challenges and opportunities [4][9] - The company is committed to enhancing its operational quality and creating sustainable returns for investors through improved communication and engagement [6][9] - The company is advancing a corn protein processing project with an annual capacity of 100,000 tons, expected to be operational by 2025, to optimize product structure and create new revenue streams [9][10]

2、本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 （一）会议召开时间： 证券代码：301156 证券简称：美农生物 公告编号：2025-036 上海美农生物科技股份有限公司 2024 年年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会不存在否决议案的情形； 1、现场会议召开时间：2025 年 5 月 16 日（星期五）14:30； 2、网络投票时间：通过深圳证券交易所（以下简称"深交所"）交易系统进 行网络投票的具体时间为：2025 年 5 月 16 日 9:15-9:25、9:30-11:30 和 13:00-15:00； 通过深交所互联网投票系统投票的具体时间为：2025 年 5 月 16 日 9:15-15:00。 （二）召开地点：上海市嘉定区沥红路 151 号公司会议室 （三）召开方式：采取现场投票与网络投票相结合的方式 （四）召集人：上海美农生物科技股份有限公司（以下简称"公司"）董事会 （五）会议主持人：董事长洪伟先生 （六）本次股东大会的召集、召开及表决程序符合《中华人 ...

北京市天元律师事务所 关于上海美农生物科技股份有限公司 致：上海美农生物科技股份有限公司 上海美农生物科技股份有限公司（以下简称"公司"）2024 年年度股东大会（以 下简称"本次股东大会"）采用现场投票与网络投票相结合的方式召开，现场会议于 2025 年 5 月 16 日 14:30 在上海市嘉定区沥红路 151 号公司会议室召开。北京市天 元律师事务所（以下简称"本所"）接受公司聘任，指派本所律师参加本次股东大会 现场会议，并根据《中华人民共和国公司法》、《中华人民共和国证券法》（以下 简称"《证券法》"）、《上市公司股东会规则》（以下简称"《股东会规则》"）以 及《上海美农生物科技股份有限公司章程》（以下简称"《公司章程》"）等有关规 定，就本次股东大会的召集、召开程序、出席会议人员的资格、召集人资格、会议 表决程序和表决结果等有关事宜出具本法律意见。 为出具本法律意见，本所律师审查了《上海美农生物科技股份有限公司第五届 董事会第十一次会议决议公告》《上海美农生物科技股份有限公司第五届监事会第 十次会议决议公告》《上海美农生物科技股份有限公司关于召开 2024 年年度股东 大会的通知》（以下简称"《召开 ...

Group 1 - The pet economy concept rose by 1.98%, ranking third among concept sectors, with 54 stocks increasing in value, including major gainers like Meino Biological and Jieya Co., which hit the 20% limit up [1][2] - Notable stocks with significant increases include Xianle Health, Huisheng Biological, and Yiyuan Magic Yam, which rose by 13.41%, 10.50%, and 9.10% respectively [1] - The leading decliners in the sector were Zhiou Technology, Qingmu Technology, and Yingstone Network, which fell by 4.64%, 4.42%, and 2.73% respectively [1] Group 2 - The pet economy sector saw a net inflow of 236 million yuan, with 48 stocks receiving net inflows, and 7 stocks attracting over 30 million yuan each [2] - The top stock for net inflow was Yong'an Pharmaceutical, with a net inflow of 68.36 million yuan, followed by Jieya Co., Ruoyuchen, and Meino Biological with net inflows of 48.24 million yuan, 46.14 million yuan, and 45.47 million yuan respectively [2][3] Group 3 - In terms of net inflow ratios, Jieya Co., Jiabiyou, and Meino Biological led with net inflow rates of 27.98%, 13.31%, and 11.04% respectively [3] - The pet economy sector's inflow ranking included stocks like Yong'an Pharmaceutical, Jieya Co., Ruoyuchen, and Meino Biological, all showing strong performance in terms of trading volume and turnover rates [3][4]

Group 1 - The vitamin concept sector rose by 1.55%, ranking 6th among concept sectors, with 48 stocks increasing in value, including Meino Biological reaching a 20% limit up [1][2] - Notable gainers in the vitamin sector included Xiwang Food, Yong'an Pharmaceutical, and Jindawei, which all hit the limit up, while Xianle Health, Oukang Pharmaceutical, and Fujilai also saw significant increases of 13.41%, 8.31%, and 6.54% respectively [1][2] - The sector experienced a net inflow of 548 million yuan from main funds, with 41 stocks receiving net inflows, and 8 stocks exceeding 30 million yuan in net inflow, led by Jindawei with 155 million yuan [2][3] Group 2 - The top stocks by net inflow ratio included Jindawei, Xiwang Food, and Andisu, with net inflow ratios of 29.36%, 27.57%, and 20.19% respectively [3][4] - The trading volume and turnover rates for leading stocks in the vitamin sector were significant, with Jindawei showing a turnover rate of 4.82% and a price increase of 9.99% [3][4] - Other notable stocks included Yong'an Pharmaceutical with a 9.99% increase and a turnover rate of 31.54%, and Zhejiang Pharmaceutical with a modest increase of 0.29% [3][4]